Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer
Purpose: The aim of this prospective study was to assess the prognostic impact of serum tumor markers (Cyfra21-1, carcinoembryonic antigen, neuron-specific enolase, squamous cell carcinoma-antigen and TPAcyk) in patients with non-small cell lung cancer (NSCLC) receiving complete resection. Methods:...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2002-06, Vol.36 (3), p.265-270 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 270 |
|---|---|
| container_issue | 3 |
| container_start_page | 265 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 36 |
| creator | Reinmuth, Niels Brandt, Burkhard Semik, Michael Kunze, Wolf-Peter Achatzy, Richard Scheld, Hans H. Broermann, Petra Berdel, Wolfgang E. Macha, Hans N. Thomas, Michael |
| description | Purpose: The aim of this prospective study was to assess the prognostic impact of serum tumor markers (Cyfra21-1, carcinoembryonic antigen, neuron-specific enolase, squamous cell carcinoma-antigen and TPAcyk) in patients with non-small cell lung cancer (NSCLC) receiving complete resection.
Methods: Sixty-seven patients with histologically proven NSCLC and complete resection of stage I–IIIA disease were included. The serum levels of all markers were measured using commercially available immunoassays.
Results: With a median follow-up of 86 months for surviving patients, those with initial Cyfra21-1 serum levels higher than 3.57 ng/ml had a significantly worse prognosis (
P=0.014). The remaining serum tumor markers showed no prognostic impact. In a Cox regression model, Cyfra21-1 proved to be an independent prognostic factor for both overall survival and disease-free interval. In addition, Cyfra21-1 sustained as an independent prognostic factor in completely resected stage I/II disease.
Conclusions: With a cut-off value of 3.57 ng/ml, Cyfra 21-1 was an independent prognostic factor for survival in NSCLC-patients with complete resection. Further evaluation is needed, particularly in stage I/II disease. When the prognostic impact is confirmed with larger patient numbers this may contribute to the identification of stratification variables for future treatment approaches of NSCLC. |
| doi_str_mv | 10.1016/S0169-5002(02)00009-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71691823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500202000090</els_id><sourcerecordid>71691823</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-3a4ff2ea7cfde63f7a6fbcf6d183d06e563ee0e987f3d352ebc1ab7d2ac6fd2d3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMoWqs_QclF0cNqPtrs7kmk-AWCgnoOaTLR6G5Sk12h_96sLXo0DJPLM8k7D0IHlJxRQsX5U251MSWEnRB2SvKpC7KBRrQqWVFxzjbR6BfZQbspvRNCS0rqbbRDWcYZFyP09hjDqw-pcxq7dqF0h4PFs6WNitGCYuUNDt0bRJwg9i1uVfyAmLDzWId20UAHzRJHSKA7MNgHX6RWNQ3WkFvT-1esldcQ99CWVU2C_fU9Ri_XV8-z2-L-4eZudnlf6MmEdwVXE2sZqFJbA4LbUgk711YYWnFDBEwFByBQV6Xlhk8ZzDVV89IwpYU1zPAxOl69u4jhs4fUydalIYzyEPoky-yEVoxncLoCdQwpRbByEV1ebykpkYNi-aNYDv7kUINiSfLc4fqDft6C-ZtaO83A0RpQSasmm_TapT-OC1HReghwseIg6_hyEGXSDrIr42K2KU1w_0T5BjgSmdg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71691823</pqid></control><display><type>article</type><title>Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Reinmuth, Niels ; Brandt, Burkhard ; Semik, Michael ; Kunze, Wolf-Peter ; Achatzy, Richard ; Scheld, Hans H. ; Broermann, Petra ; Berdel, Wolfgang E. ; Macha, Hans N. ; Thomas, Michael</creator><creatorcontrib>Reinmuth, Niels ; Brandt, Burkhard ; Semik, Michael ; Kunze, Wolf-Peter ; Achatzy, Richard ; Scheld, Hans H. ; Broermann, Petra ; Berdel, Wolfgang E. ; Macha, Hans N. ; Thomas, Michael</creatorcontrib><description>Purpose: The aim of this prospective study was to assess the prognostic impact of serum tumor markers (Cyfra21-1, carcinoembryonic antigen, neuron-specific enolase, squamous cell carcinoma-antigen and TPAcyk) in patients with non-small cell lung cancer (NSCLC) receiving complete resection.
Methods: Sixty-seven patients with histologically proven NSCLC and complete resection of stage I–IIIA disease were included. The serum levels of all markers were measured using commercially available immunoassays.
Results: With a median follow-up of 86 months for surviving patients, those with initial Cyfra21-1 serum levels higher than 3.57 ng/ml had a significantly worse prognosis (
P=0.014). The remaining serum tumor markers showed no prognostic impact. In a Cox regression model, Cyfra21-1 proved to be an independent prognostic factor for both overall survival and disease-free interval. In addition, Cyfra21-1 sustained as an independent prognostic factor in completely resected stage I/II disease.
Conclusions: With a cut-off value of 3.57 ng/ml, Cyfra 21-1 was an independent prognostic factor for survival in NSCLC-patients with complete resection. Further evaluation is needed, particularly in stage I/II disease. When the prognostic impact is confirmed with larger patient numbers this may contribute to the identification of stratification variables for future treatment approaches of NSCLC.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/S0169-5002(02)00009-0</identifier><identifier>PMID: 12009236</identifier><identifier>CODEN: LUCAE5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Antigens, Neoplasm - blood ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Carcinoembryonic Antigen - blood ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - surgery ; Cyfra21-1 ; Early stage disease ; Female ; Follow-Up Studies ; Humans ; Keratin-19 ; Keratins ; Long-term follow-up ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Male ; Medical sciences ; Non-small cell lung cancer ; Phosphopyruvate Hydratase - blood ; Prognosis ; Prognostic factor ; Proportional Hazards Models ; Prospective Studies ; Prospective study ; Regression Analysis ; Serpins ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the respiratory system ; Survival Analysis ; Tissue Polypeptide Antigen - blood</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2002-06, Vol.36 (3), p.265-270</ispartof><rights>2002 Elsevier Science Ireland Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-3a4ff2ea7cfde63f7a6fbcf6d183d06e563ee0e987f3d352ebc1ab7d2ac6fd2d3</citedby><cites>FETCH-LOGICAL-c443t-3a4ff2ea7cfde63f7a6fbcf6d183d06e563ee0e987f3d352ebc1ab7d2ac6fd2d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0169500202000090$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13668193$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12009236$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reinmuth, Niels</creatorcontrib><creatorcontrib>Brandt, Burkhard</creatorcontrib><creatorcontrib>Semik, Michael</creatorcontrib><creatorcontrib>Kunze, Wolf-Peter</creatorcontrib><creatorcontrib>Achatzy, Richard</creatorcontrib><creatorcontrib>Scheld, Hans H.</creatorcontrib><creatorcontrib>Broermann, Petra</creatorcontrib><creatorcontrib>Berdel, Wolfgang E.</creatorcontrib><creatorcontrib>Macha, Hans N.</creatorcontrib><creatorcontrib>Thomas, Michael</creatorcontrib><title>Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Purpose: The aim of this prospective study was to assess the prognostic impact of serum tumor markers (Cyfra21-1, carcinoembryonic antigen, neuron-specific enolase, squamous cell carcinoma-antigen and TPAcyk) in patients with non-small cell lung cancer (NSCLC) receiving complete resection.
Methods: Sixty-seven patients with histologically proven NSCLC and complete resection of stage I–IIIA disease were included. The serum levels of all markers were measured using commercially available immunoassays.
Results: With a median follow-up of 86 months for surviving patients, those with initial Cyfra21-1 serum levels higher than 3.57 ng/ml had a significantly worse prognosis (
P=0.014). The remaining serum tumor markers showed no prognostic impact. In a Cox regression model, Cyfra21-1 proved to be an independent prognostic factor for both overall survival and disease-free interval. In addition, Cyfra21-1 sustained as an independent prognostic factor in completely resected stage I/II disease.
Conclusions: With a cut-off value of 3.57 ng/ml, Cyfra 21-1 was an independent prognostic factor for survival in NSCLC-patients with complete resection. Further evaluation is needed, particularly in stage I/II disease. When the prognostic impact is confirmed with larger patient numbers this may contribute to the identification of stratification variables for future treatment approaches of NSCLC.</description><subject>Antigens, Neoplasm - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Cyfra21-1</subject><subject>Early stage disease</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Keratin-19</subject><subject>Keratins</subject><subject>Long-term follow-up</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Non-small cell lung cancer</subject><subject>Phosphopyruvate Hydratase - blood</subject><subject>Prognosis</subject><subject>Prognostic factor</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Prospective study</subject><subject>Regression Analysis</subject><subject>Serpins</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the respiratory system</subject><subject>Survival Analysis</subject><subject>Tissue Polypeptide Antigen - blood</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhoMoWqs_QclF0cNqPtrs7kmk-AWCgnoOaTLR6G5Sk12h_96sLXo0DJPLM8k7D0IHlJxRQsX5U251MSWEnRB2SvKpC7KBRrQqWVFxzjbR6BfZQbspvRNCS0rqbbRDWcYZFyP09hjDqw-pcxq7dqF0h4PFs6WNitGCYuUNDt0bRJwg9i1uVfyAmLDzWId20UAHzRJHSKA7MNgHX6RWNQ3WkFvT-1esldcQ99CWVU2C_fU9Ri_XV8-z2-L-4eZudnlf6MmEdwVXE2sZqFJbA4LbUgk711YYWnFDBEwFByBQV6Xlhk8ZzDVV89IwpYU1zPAxOl69u4jhs4fUydalIYzyEPoky-yEVoxncLoCdQwpRbByEV1ebykpkYNi-aNYDv7kUINiSfLc4fqDft6C-ZtaO83A0RpQSasmm_TapT-OC1HReghwseIg6_hyEGXSDrIr42K2KU1w_0T5BjgSmdg</recordid><startdate>20020601</startdate><enddate>20020601</enddate><creator>Reinmuth, Niels</creator><creator>Brandt, Burkhard</creator><creator>Semik, Michael</creator><creator>Kunze, Wolf-Peter</creator><creator>Achatzy, Richard</creator><creator>Scheld, Hans H.</creator><creator>Broermann, Petra</creator><creator>Berdel, Wolfgang E.</creator><creator>Macha, Hans N.</creator><creator>Thomas, Michael</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020601</creationdate><title>Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer</title><author>Reinmuth, Niels ; Brandt, Burkhard ; Semik, Michael ; Kunze, Wolf-Peter ; Achatzy, Richard ; Scheld, Hans H. ; Broermann, Petra ; Berdel, Wolfgang E. ; Macha, Hans N. ; Thomas, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-3a4ff2ea7cfde63f7a6fbcf6d183d06e563ee0e987f3d352ebc1ab7d2ac6fd2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antigens, Neoplasm - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Cyfra21-1</topic><topic>Early stage disease</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Keratin-19</topic><topic>Keratins</topic><topic>Long-term follow-up</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Non-small cell lung cancer</topic><topic>Phosphopyruvate Hydratase - blood</topic><topic>Prognosis</topic><topic>Prognostic factor</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Prospective study</topic><topic>Regression Analysis</topic><topic>Serpins</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the respiratory system</topic><topic>Survival Analysis</topic><topic>Tissue Polypeptide Antigen - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reinmuth, Niels</creatorcontrib><creatorcontrib>Brandt, Burkhard</creatorcontrib><creatorcontrib>Semik, Michael</creatorcontrib><creatorcontrib>Kunze, Wolf-Peter</creatorcontrib><creatorcontrib>Achatzy, Richard</creatorcontrib><creatorcontrib>Scheld, Hans H.</creatorcontrib><creatorcontrib>Broermann, Petra</creatorcontrib><creatorcontrib>Berdel, Wolfgang E.</creatorcontrib><creatorcontrib>Macha, Hans N.</creatorcontrib><creatorcontrib>Thomas, Michael</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reinmuth, Niels</au><au>Brandt, Burkhard</au><au>Semik, Michael</au><au>Kunze, Wolf-Peter</au><au>Achatzy, Richard</au><au>Scheld, Hans H.</au><au>Broermann, Petra</au><au>Berdel, Wolfgang E.</au><au>Macha, Hans N.</au><au>Thomas, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2002-06-01</date><risdate>2002</risdate><volume>36</volume><issue>3</issue><spage>265</spage><epage>270</epage><pages>265-270</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><coden>LUCAE5</coden><abstract>Purpose: The aim of this prospective study was to assess the prognostic impact of serum tumor markers (Cyfra21-1, carcinoembryonic antigen, neuron-specific enolase, squamous cell carcinoma-antigen and TPAcyk) in patients with non-small cell lung cancer (NSCLC) receiving complete resection.
Methods: Sixty-seven patients with histologically proven NSCLC and complete resection of stage I–IIIA disease were included. The serum levels of all markers were measured using commercially available immunoassays.
Results: With a median follow-up of 86 months for surviving patients, those with initial Cyfra21-1 serum levels higher than 3.57 ng/ml had a significantly worse prognosis (
P=0.014). The remaining serum tumor markers showed no prognostic impact. In a Cox regression model, Cyfra21-1 proved to be an independent prognostic factor for both overall survival and disease-free interval. In addition, Cyfra21-1 sustained as an independent prognostic factor in completely resected stage I/II disease.
Conclusions: With a cut-off value of 3.57 ng/ml, Cyfra 21-1 was an independent prognostic factor for survival in NSCLC-patients with complete resection. Further evaluation is needed, particularly in stage I/II disease. When the prognostic impact is confirmed with larger patient numbers this may contribute to the identification of stratification variables for future treatment approaches of NSCLC.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>12009236</pmid><doi>10.1016/S0169-5002(02)00009-0</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2002-06, Vol.36 (3), p.265-270 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71691823 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antigens, Neoplasm - blood Biological and medical sciences Biomarkers, Tumor - blood Carcinoembryonic Antigen - blood Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Cyfra21-1 Early stage disease Female Follow-Up Studies Humans Keratin-19 Keratins Long-term follow-up Lung Neoplasms - pathology Lung Neoplasms - surgery Male Medical sciences Non-small cell lung cancer Phosphopyruvate Hydratase - blood Prognosis Prognostic factor Proportional Hazards Models Prospective Studies Prospective study Regression Analysis Serpins Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the respiratory system Survival Analysis Tissue Polypeptide Antigen - blood |
| title | Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A58%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20impact%20of%20Cyfra21-1%20and%20other%20serum%20markers%20in%20completely%20resected%20non-small%20cell%20lung%20cancer&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Reinmuth,%20Niels&rft.date=2002-06-01&rft.volume=36&rft.issue=3&rft.spage=265&rft.epage=270&rft.pages=265-270&rft.issn=0169-5002&rft.eissn=1872-8332&rft.coden=LUCAE5&rft_id=info:doi/10.1016/S0169-5002(02)00009-0&rft_dat=%3Cproquest_cross%3E71691823%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71691823&rft_id=info:pmid/12009236&rft_els_id=S0169500202000090&rfr_iscdi=true |